Biolex, Inc.
Biolex, Inc. is a North Carolina based biopharmaceutical company devoted to discovering, developing and commercializing its proprietary advanced protein expression technology for the development of human therapeutics. Biolex' strategy focuses on the development of Biolex proteins as well as those obtained from partner companies. The firm's corporate partners include Bayer Corporation, Centocor, Inc., Debiopharm S.A., and a major pharmaceutical company. The Company's headquarters and laboratory facility are based in Pittsboro, North Carolina. The company's LEX System (TM) for the expression of human therapeutic proteins couples the ideal natural characteristics of the green aquatic plant, Lemna, with advanced genetic engineering and protein recovery methods. The LEX System (TM) uniquely combines the most desired qualities of mammalian cell culture, the current gold standard among existing expression systems (clonal replication, fast growth, high protein content, secretion of the target protein into the media, a contained and controlled environment), with the most sought after characteristics in next generation systems (speed of scale-up, significantly reduced capital requirement, low operating costs).
| Company | Biolex, Inc. |
|---|---|
| URL | http://www.biolex.com/ |
MANUFACTURER OF LOCTERON® DRUG SUBSTANCE FOR PHASE 3 TRIALS
BIOLEX ANNOUNCES ORAL PRESENTATION OF PRECLINICAL RESULTS FOR DIRECT-ACTING THROMBOLYTIC BLX-155 AT ISTH MEETING
Preclinical Results Show Superior Thrombolytic Activity for BLX-155 Compared to t-PA
Biolex Therapeutics, Inc. announced today the commencement of patient dosing in the SELECT-2 Phase 2b trial of its lead product candidate Locteron for the treatment of chronic hepatitis C.
Biolex Therapeutics Completes $60 Million Series D Financing to Accelerate Development of Locteron® in Hepatitis C
Financing Led by Clarus Ventures
It was announced today that Biolex Therapeutics has secured a $10.5 million growth capital loan from Silicon Valley Bank and Oxford Finance Corporation.
MRC Technology (MRCT) (London, UK) and Biolex Therapeutics, Inc. (Pittsboro, North Carolina, USA) announced today that MRCT had successfully completed the humanization of a novel antibody targeting CD20, indicated in non-Hodgkin's lymphoma and rheumatoid arthritis. Biolex is applying its proprietary glycosylation optimization technology to the antibody, BLX-301, to enhance efficacy and potency of the product candidate and potentially reduce certain side effects.
Biolex Therapeutics Researchers Present Locteron® Phase 2a Hepatitis C Trial Results at EASL Conference
Biolex Therapeutics, Inc. announced that the results from its SELECT-1 Phase 2a clinical trial of Locteron® will be presented today at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL).
Biolex Announces Presentation of Preclinical Results for Clot Buster Blx-155 at Sir Annual Scientific Meeting
Biolex Therapeutics, Inc. announced today that researchers presented results at the 33rd Annual Scientific Meeting of the Society of Interventional Radiology (SIR) in Washington,
Biolex Announces Publication of Phase 1 Locteron® Results of Interferon & Cytokine Research
PITTSBORO, NORTH CAROLINA, March 12, 2008 - Biolex Therapeutics, Inc. today announced the publication of results of a Phase 1 clinical trial of Locteron®,
PITTSBORO, NORTH CAROLINA, February 19, 2008 - Biolex Therapeutics today announced that it has entered into an agreement with Merck KGaA,
Biolex Therapeutics Commences United States Phase 2a Trial of Locteronr® in Hepatitis C
Biolex Therapeutics, Inc. today announced the commencement of patient dosing in a United States Phase 2a clinical trial of its lead product candidate Locteron for the treatment of hepatitis C.
Biolex Researchers Present Results of Anti-Cd20 Antibody with Optimized Glycosylation at Ash Conference
Preclinical Results Demonstrate Potential for Improved Efficacy and Potency and Reduced Side Effects Compared to Rituxan®
Biolex Therapeutics Researchers Present Locteron(Tm) Phase 2a Hepatitis C Trial Results at Aasld Conference
Phase 2a Trial Demonstrates Statistically Significant Dose Response
Biolex Therapeutics’Locteron(Tm) Phase 2a Hepatitis C Trial Results Selected for Presentation at Aasld Conference
Biolex Also Announces Top-Line Data from Complete Phase 2a Trial Highlighting Favorable Viral Response and Tolerability Results
Biolex Therapeutics Announces Positive Phase 2a Results For Hepatitis C Product Candidate Locteron(TM)
PITTSBORO, NORTH CAROLINA, JULY 26, 2007 - Biolex Therapeutics today announced successful initial results from the SELECT-1 Phase 2a clinical trial of Locteron?, the first controlled-release interferon alfa being developed for the treatme...
PITTSBORO, NORTH CAROLINA, JULY 13, 2007 - Biolex Therapeutics announced today that Company researchers have presented ...
PITTSBORO, NC, May 24, 2007 - Biolex Therapeutics, a privately held biopharmaceutical company, announced today the closing of a $30 million Series C financing. The financing was led by Investor Growth Capital of New York and included the parti...
PITTSBORO, NORTH CAROLINA, May 7, 2007 -- Biolex Therapeutics today announced an agreement with Genmab A/S, a leading antibody development company. Under the agreement Genmab will evaluate Biolex’s patented LEX SystemSM as a potenti...
Biolex Therapeutics'LEX Systems(SM) Featured In Breakout Session At The 2007 Bio International Convention
PITTSBORO, NORTH CAROLINA, May 3, 2007 - Biolex Therapeutics today announced that its LEX SystemSM technology for enabling hard-to-make proteins and optimizing monoclonal antibodies will be featured at the "Prevention and Cure: Cont...
Biolex Therapeutics Announces Strategic Collaboration With Merial For Animal Health Vaccines
PITTSBORO, NORTH CAROLINA, May 1, 2007 - Biolex Therapeutics today announced a strategic collaboration with Merial Limited, a world-leader in ani...
PITTSBORO, NORTH CAROLINA, March 26, 2007 - Biolex Therapeutics today announced that it will be presenting at the Future Leaders in the Biotech Industry conference hosted by BioCentury and Thomson Financial on Thursday, March 29, 2007 at the M...
First Protein Expression System to Produce Commercially Viable Levels of Full-Length Recombinant Plasmin
Biolex Therapeutics Featured At Next Generation Antibody Panel At BIO CEO & Investor Conference
PITTSBORO, NORTH CAROLINA, February 13, 2007 - Biolex Therapeutics today announced that its technology for optimizing monoclonal antibodies will be featured at the “Next Generation Antibodies and Antibody Technologies” session at the 9th Annua...
Biolex Therapeutics Announces Initiation Of Locterontm(TM) Phase 2 Clinical Study In Chronic Hepatitis C
PITTSBORO, NORTH CAROLINA, January 30, 2007 - Biolex Therapeutics today announced the initiation of a Phase 2a clinical trial of its lead product candidate LocteronTM, a best-in-class controlled-release interferon alfa. Locteron is being devel...
Biolex Therapeutics today announced that it will be presenting at the 25th Annual JP Morgan Healthcare Conference on Thursday, January 11, 2007, at 1:30 p.m. PST in the Elizabethan C/D room of the Westin St.Francis Hotel in San Francisco. During the ...
PITTSBORO, NORTH CAROLINA, November 28, 2006 - Biolex Therapeutics today announced results published in Nature Biotechnology demonstrating the ability of its proprietary LEX SystemSMto produce monoclonal antibodies that have enhance...
PITTSBORO, NORTH CAROLINA, November 15, 2006 - Biolex Therapeutics, a protein therapeutics company, today announced that it was recognized as the Top Venture Company of the year by the North Carolina Technology Association (NCTA) at its annual...
Biolex Therapeutics Featured At The 9th Annual Facilities For Mammalian Cell Product Conference
PITTSBORO, NORTH CAROLINA, October 18, 2006 - Biolex Therapeutics today announced that Glen Williams, Senior Vice President, Operations, presented its proprietary LEX Systemsm yesterday at the 9th Annual Facilities for Mammalian Cel...
Biolex Therapeutics Announces Positive Phase 1 Results for Hepatitis C Product Candidate Locteron(TM)
Results Support Dosing Every Two Weeks with Potential for Improved Side Effect Profile Over Current Therapies
Agreement Expanded to Include Three Medarex Monoclonal Antibodies
PITTSBORO, NORTH CAROLINA, MARCH 22, 2006 - Biolex Therapeutics was awarded special merit recognition in a global competition for excellence in pharmaceutical manufacturing facilities. Biolex was presented the award in New York at the INTERPHE...
Biolex Therapeutics Presents Results Highlighting Benefits Of Locteron(TM) At "Breakthroughs In Hepatitis" Session
Pittsboro, North Carolina, February 15, 2006 - Biolex Therapeutics announced today that its lead candidate Locteron was featured at the "Breakthroughs in Hepatitis" session at the BIO CEO & Investor Conference yesterday in New York. Mr. Jan Tu...
PITTSBORO, NORTH CAROLINA, November 16, 2005 - Biolex Therapeutics, a protein therapeutics company, announced today three new additions to its management team. Each of these pharmaceutical executives brings a proven track record in the develo...
PITTSBORO, NORTH CAROLINA, November 2, 2005 - Biolex Therapeutics today announced the dosing of the first cohort of subjects in a Phase 1 study of Locteron, a next-generation controlled-release form of alfa interferon. Biolex is co-devel...
Biolex Therapeutics And Kringle Pharma Announce Collaboration For Production Of A Novel Protein Targeting Cancer
PITTSBORO, NORTH CAROLINA/OSAKA, JAPAN, October 27, 2005 - Biolex Therapeutics, a protein therapeutics company, and Kringle Pharma, Inc., a biopharmaceutical company developing cancer therapeutics, have formed a collaboration under which Biole...
Biolex Therapeutics Successfully Completes Phase 1 Study For First LEX System Produced Therapeutic Protein
PITTSBORO, NORTH CAROLINA, October 26, 2005 - Biolex Therapeutics, a protein therapeutics company, today announced the successful completion of a Phase 1 clinical trial of BLX-883, a form of alfa interferon. BLX-883 is the first clinical-stage...
Biolex Therapeutics Doubles Manufacturing Capacity, Realizing Singnificant Economic And Time Efficienceis
PITTSBORO, NC, September 13, 2005 - Biolex Therapeutics, a venture backed, clinical stage protein therapeutics company, today ...
PITTSBORO, NC, September 1, 2005 Biolex Therapeutics, a venture backed, clinical stage protein therapeutics company, today announced that it has raised $36 million in a Series B financing led by Polaris Venture Partners. The financing was oversubsc...
PITTSBORO, NC, MARCH 31, 2005: Biolex, Inc., a privately held protein therapeutics company, today announced the issuance of a patent that broadly claims methods for i...
Biolex Forms Broad Strategic Alliance With Centocor
PITTSBORO, NC, MARCH 21, 2005 Biolex, Inc., a privately held protein therapeutics company, today announced a broad-based, multi-leveled strategic alliance with Centocor,Inc., a leading bioph...
PITTSBORO, NC, FEBRUARY 4, 2005: Biolex, Inc., a privately held protein therapeutics company, today announced the signing of a new agreement with Medar...
Biolex Submits Ind and Cta For Blx-883, a Form of Alfa Interferon Manufactured with the Biolex Lex Systems
PITTSBORO, NC JANUARY 6, 2005: Biolex, Inc., a privately held protein therapeutics company, today announced the submission of an IND to the US FDA and a CTA to the UK MHRA ...
PITTSBORO, NC, OCTOBER 6, 2004: Biolex, Inc., a privately held protein therapeutics company, announced today an expanded collaboration with Centocor, Inc. a wholly owned subsidiary of Johnson & Johnson, to include two additional proteins.
PITTSBORO, NC, SEPTEMBER 27, 2004: Biolex, Inc., a privately held protein therapeutics company, hosted today the Opening Ceremonies and Ribbon Cutting for its new clinical biomanufacturing facility. Honored guests attending the celebration inc...
PITTSBORO, NC, August 31, 2004: Biolex, Inc., a privately held protein therapeutics company, announced today the appoin...
06/17/2008 | Taro InabaBoehringer Ingelheim announced an agreement to acquire Actimis Pharmaceuticals, Inc. one of our portfolio firms.
11/01/2007 | Nobuhiro Shimizu【Announcement of the Establishment of Beijing Office】
We are pleased to announce that Mitsui Ventures has opened a new office in Beijing in September2007.
07/18/2007 | Taro InabaMitsui Ventures Launching a New Approach to Seed Financing